Alternate Name(s):
Tazocin
Classification:
Antibiotic with B-Lactamase Inhibitor
Original Date:
August 2003
Revised Date:
Sept 2026
Indications:
- Treatment of severe infections caused by susceptible B-Lactamase producing strains. Tazobactam expands activity of piperacillin to include B-Lactamase producing strains of S.aureus, H. influenza, B. fragilis, Klebsiella, E. Coli and Acinetobacter.
Administration:
- IV intermittent infusion: over 30 minutes
Dosage:
| Weight | PNA | Dose |
| < 2kg | 0 to 7 days | 300 mg/kg/day divided Q8H |
| 8 to 28 days |
320 mg/kg/day divided Q6H |
|
| > 2kg | 0 to 7 days | |
| 8 to 28 days |
Side Effects:
- CVS: hypotension, hypertension, edema
- Endocrine and metabolic: hypokalemia
- Hematologic: anemia, leukopenia, eosinophilia, prolonged prothrombin time
- Hepatic: increased AST,ALT, bilirubin, jaundice
- Local: phlebitis
- Renal: BUN and serum creatinine elevated, interstitial nephritis
Parameters to Monitor:
- LFTs, bleeding time
- CBC
- Serum electrolytes
- Renal function
Reconstitution and Stability:
IV Intermittent infusion:
CHEO:
- Piperacillin (P)/Tazobactam (T) 4 g(P)/0.5 g(T) vial (doses < 200 mg)
- Add 36.8 mL SWFI to vial
- Take 4 mL (400 mg) and add to 16 mL D5W
- Final concentration: 20 mg/mL (P)
- Piperacillin (P)/Tazobactam (T) 4 g(P)/0.5 g(T) vial (doses > 200 mg)
- Add 36.8 mL SWFI to vial
- Final concentration: 100 mg/mL (P)
TOH:
- Piperacillin (P)/Tazobactam (T) 3 g(P)/0.375 g(T) vial
- Add 15 mL SWFI to vial
- Take 2.3 mL (400 mg) and add to 18 mL D5W
- Final concentration: 20 mg/mL (P)
Compatibility:
- Solutions Compatible: D5W, 0.9% NaCl
- Y-site Compatible: calcium gluconate, dexmedetomidine, dopamine, fluconazole, furosemide, heparin, milrinone, morphine, potassium chloride, ranitidine, SMOF, TPN, vasopressin
Incompatible: acyclovir, azithromycin, dobutamine, gentamicin, tobramycin, vancomycin
- Due to the potential inactivation of aminoglycosides and piperacillin/tazobactam, it is preferable to separate administration of these antibiotics by 30-60 minutes.
References:
- Taketomo CK, Hodding JH, Kraus DM. Pediatric Dosage Handbook 22nd Edition. Hudson: Lexi-Comp Inc.; 2015
- American Society on Health-System Pharmacists (ASHP). Handbook on Injectable Drugs. 19th Edition. Bethesda: American Society of Health-System Pharmacists; 2017
- Bradley JS, Nelson JD, Barnett ED, et al, eds. Nelson's Pediatric Antimicrobial Therapy. 30th ed. American Academy of Pediatrics; 2024